Gland Pharma Schedules Investor Meetings from Sep 3 to Sep 24, 2026
Gland Pharma Limited will hold a series of Analyst and Institutional Investor Meetings from September 3 to September 24, 2026. The meetings include one-on-one sessions with Carnelian Capital, First Ray Capital, WCM Investment, and LIC MF, as well as group meetings and participation in the BofA Securities 2026 Asia Pacific Conference.
This is a routine communication regarding upcoming investor engagements and does not immediately impact the company's operations or financial standing.
The announcement is a routine intimation of scheduled investor meetings and does not contain any specific financial or business performance data that would indicate a positive or negative sentiment.
Gland Pharma Limited has announced the schedule for its upcoming Analyst and Institutional Investor Meetings. These meetings are set to take place throughout September 2026, commencing on September 3rd and concluding on September 24th. The company will engage in one-on-one meetings with various investors including Carnelian Capital on September 3rd, First Ray Capital and WCM Investment (arranged by Jefferies) on September 4th, and LIC MF (arranged by 360One) on September 7th. Further group meetings are scheduled with entities arranged by ICICI Securities on September 18th and by JP Morgan on September 24th. Additionally, Gland Pharma will participate in the BofA Securities 2026 Asia Pacific Conference, involving one-on-one and group meetings, from September 21st to September 22nd. The company has cautioned that this schedule is subject to change due to unforeseen circumstances affecting the investors, analysts, or the company itself.
A plain-language summary of a public exchange filing by Gland Pharma Limited. Read the original for the full detail.